Emmaus Life Sciences Q3 2025 Earnings Results & Report

Emmaus Life Sciences EPS Results

• Actual EPS: -$0.03
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Emmaus Life Sciences Revenue Results

• Actual Revenue: $3.38 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Emmaus Life Sciences (OTCMKTS:EMMA) is a biopharmaceutical company focused primarily on developing and commercializing treatments for rare and serious diseases. The company’s best-known product is Endari (L-glutamine), an oral powder approved by the U.S. Food and Drug Administration to reduce the acute complications of sickle cell disease in adults and children aged five and older.

Historically, Emmaus has concentrated on therapies for sickle cell disease and other conditions with significant unmet medical needs. Its activities have included product development, regulatory submissions, manufacturing, and commercialization, with Endari serving as its principal marketed therapy. The company has also investigated additional applications for L-glutamine and other potential treatments.

Emmaus Life Sciences has been based in California and has served the U.S. market through its pharmaceutical operations. Publicly available information about the company’s current operations and leadership is limited, so details regarding its present management structure and geographic reach may have changed.